| Literature DB >> 29485508 |
Michael Charlton1, Josh Levitsky2, Bashar Aqel3, John OʼGrady4, Julie Hemibach5, Mary Rinella2, John Fung1, Marwan Ghabril6, Ray Thomason7, Patrizia Burra8, Ester Coelho Little9, Marina Berenguer10, Abraham Shaked11, James Trotter12, John Roberts13, Manuel Rodriguez-Davalos14, Mohamed Rela4, Elizabeth Pomfret15, Caroline Heyrend14, Juan Gallegos-Orozco7, Faouzi Saliba16.
Abstract
Effective immunosupression management is central to achieving optimal outcomes in liver transplant recipients. Current immunosuppression regimens and agents are highly effective in minimizing graft loss due to acute and chronic rejection but can also produce a substantial array of toxicities. The utilization of immunosuppression varies widely, contributing to the wide disparities in posttransplant outcomes reported between transplant centers. The International Liver Transplantation Society (ILTS) convened a consensus conference, comprised of a global panel of expert hepatologists, transplant surgeons, nephrologists, and pharmacologists to review the literature and experience pertaining to immunosuppression management to develop guidelines on key aspects of immunosuppression. The consensus findings and recommendations of the ILTS Consensus guidelines on immunosuppression in liver transplant recipients are presented in this article.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29485508 DOI: 10.1097/TP.0000000000002147
Source DB: PubMed Journal: Transplantation ISSN: 0041-1337 Impact factor: 4.939